GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

The newly approved radiotracer is seen as a major step forward for nuclear imaging technology. Specialists have been looking forward to its arrival on the market for quite some time.

Knowing what, exactly, is needed in cardiac PET documentation is one of the best ways to limit prior authorization issues.

As cardiac point-of-care ultrasound use continues to grow outside of traditional echo labs, the American Society of Echocardiography is working to ensure everyone is on the same page.

"The underrepresentation of women in interventional cardiology is a significant concern," according to one cardiologist behind the new campaign. 

The three-day event attracted nuclear cardiology specialists from all over the world.

SPECT is still the most common modality used to evaluate CAD patients, but cardiac PET is gaining more and more momentum.

Maros Ferencik, MD, noted that the Society of Cardiovascular Computed Tomography represents specialists from many different specialties, including cardiology, radiology and beyond.